Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

Summary

Primary Objective: To study the effect of mild, moderate and severe renal impairment on the pharmacokinetics of SAR302503. Secondary Objective: To assess the tolerability of SAR302503 given as a single 300 mg dose in subjects with mild, moderate and severe renal impairment and in matched subjects with normal renal function.

Timeline

Start

2012-11

Primary completion

2013-07

Completion

2013-07

Drugs

Indications